Cefiderocol 1g powder for solution for infusion vials
Requires a prescription from a doctor or prescriber
Siderophore cephalosporin antibiotic
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Official medicine documents
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Suspected adverse reactions reported for Cefiderocol
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
View EudraVigilance report
Suspected adverse reactions reported for Cefiderocol
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
1 branded products available
MHRA licensed products
View all licensed products for Cefiderocol on the MHRA register
Fetcroja 1g powder for concentrate for solution for infusion vials
Therapeutically similar medicines
Similarity is based on WHO Anatomical Therapeutic Chemical (ATC) classification and on a factual NHS dm+d therapeutic-grouping code prefix. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
Guidelines from the National Institute for Health and Care Excellence
NICE clinical guidance(1)
Source: National Institute for Health and Care Excellence (NICE). Contains public sector information licensed under the Open Government Licence v3.0.
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
Browse tools
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. BNF code shown is the factual mapping value distributed by NHS Business Services Authority (NHSBSA) in the dm+d supplementary file under OGL v3.0; it is not affiliated with, nor licensed from, the publishers of the British National Formulary. ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing the 50 most relevant studies.
Reviews & meta-analyses: 21 · Randomised trials: 5 · 2016–2026
Showing the 50 most relevant studies, sorted by most relevant.
Stamatis Karakonstantis, Maria Rousaki, Evangelos I. Kritsotakis
Antibiotics, 2022
Cefiderocol appears promising, as it can overcome most β-lactam resistance mechanisms (including β-lactamases, porin mutations, and efflux pumps). Resistance is uncommon according to large multinational cohorts, including against isolates resistant to carbapenems, ceftazidime/avibactam, ceftolozane/tazobactam, and colistin. However, alarming proportions of resistance have been reported in some recent cohorts (up to 50%). A systematic review was conducted in PubMed and Scopus from inception to May 2022 to review mechanisms of resistance, prevalence of heteroresistance, and in vivo emergence of resistance to cefiderocol during treatment. A variety of mechanisms, typically acting in concert, have been reported to confer resistance to cefiderocol: β-lactamases (especially NDM, KPC and AmpC variants conferring resistance to ceftazidime/avibactam, OXA-427, and PER- and SHV-type ESBLs), porin mutations, and mutations affecting siderophore receptors, efflux pumps, and target (PBP-3) modifications. Coexpression of multiple β-lactamases, often in combination with permeability defects, appears to be the main mechanism of resistance. Heteroresistance is highly prevalent (especially in A. baumannii), but its clinical impact is unclear, considering that in vivo emergence of resistance appears to be low in clinical studies. Nevertheless, cases of in vivo emerging cefiderocol resistance are increasingly being reported. Continued surveillance of cefiderocol’s activity is important as this agent is introduced in clinical practice.
Abstract licence: CC BY 4.0
Stamatis Karakonstantis, Maria Rousaki, Loukia Vassilopoulou, et al.
Clinical Microbiology and Infection, 2023
- Stenotrophomonas maltophilia
- Cefiderocol
- Anti-Bacterial Agents
Matteo Bassetti, Roger Echols, Yuko Matsunaga, et al.
The Lancet Infectious Diseases, 2020
- Cefiderocol
- Anti-Bacterial Agents
- Cephalosporins
Richard G. Wunderink, Yuko Matsunaga, Mari Ariyasu, et al.
The Lancet Infectious Diseases, 2020
- Healthcare-Associated Pneumonia
- Meropenem
- Cefiderocol
Simon Portsmouth, David van Veenhuyzen, Roger Echols, et al.
The Lancet Infectious Diseases, 2018
- Cilastatin, Imipenem Drug Combination
- Cefiderocol
- Anti-Bacterial Agents
Lorenzo Onorato, Ilaria de Luca, Caterina Monari, et al.
Journal of Infection, 2024
- Cefiderocol
- Acinetobacter Infections
- Anti-Bacterial Agents
Chuanhai Wang, Deqing Yang, Yifan Wang, et al.
Frontiers in Pharmacology, 2022
Yangyang Zhan, W. Mao, Changyun Zhao, et al.
BMC Infectious Diseases, 2024
C. Risco-Risco, C. Henriquez-Camacho, Marta Herrera-Rueda, et al.
Antibiotics, 2024
Mantsiou C, Ftergioti A, Böncüoğlu E, et al.
2026
- Gram-Negative Bacterial Infections
- Cephalosporins
- Anti-Bacterial Agents
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Pharmacology and chemical data from DrugBank
Key facts
Drug status
Approved
Major interactions
None known
Half-life
2-3 h
Mechanism
Cefiderocol acts by binding to and inhibiting penicillin-binding proteins (PBPs)…
Food interactions
None known
Human targets
None mapped
Data: DrugBank · CC BY-NC 4.0
Pharmacokinetics at a glance
Absorption
89.7 mg/L
Half-life
2-3 h
Protein binding
40-60%
Volume of distribution
18 L
Metabolism
[A189033]…
Elimination
98.6%
Clearance
5.18 L/h
Pharmacokinetic data: DrugBank · CC BY-NC 4.0
Cefiderocol was granted designation as a Qualified Infectious Disease Product and granted priority review status by the FDA on November 14, 2019.[L10893] It is indicated for use in complicated urinary tract infections in patients with limited or no alternative treatments available.[FDA Label] This indication was supported by a positive clinical trial composed of 448 patients with complicated urinary tract infections which demonstrated a 72.6% rate of symptom resolution and bacterial eradication with cefiderocol compared to 54.6% with the comparator, imipenem/cilastatin.[A189150] A concern noted in the trial was a 0.3% higher rate of all cause mortality, the cause of which has not been determined.
Known interactions with other medications. Always consult a healthcare professional.
Showing 3 of 3 interactions
How the body processes this drug — absorption, distribution, metabolism, and elimination
[A189033]
PCBA undergoes further metabolism to sulfated, methylated, and glucuronidated metabolites. The enzymes involved in these reactions have yet to be identified and cefiderocol has not been shown to interfere in the metabolism of other agents.[FDA Label]
Proteins that carry this drug through the body
PMID:19021548
Major calcium and magnesium transporter in plasma, binds approximately 45% of circulating calcium and magnesium in plasma (By similarity).
Potentially has more than two calcium-binding sites and might additionally bind calcium in a non-specific manner (By similarity). The shared binding site between zinc and calcium at residue Asp-273 suggests a crosstalk between zinc and calcium transport in the blood (By similarity). The rank order of affinity is zinc > calcium > magnesium (By similarity).
Binds to the bacterial siderophore enterobactin and inhibits enterobactin-mediated iron uptake of E.coli from ferric transferrin, and may thereby limit the utilization of iron and growth of enteric bacteria such as E.coli .
PMID:6234017
Does not prevent iron uptake by the bacterial siderophore aerobactin PMID:6234017
ATC J01DI04
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Show
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Linked compound data from DrugBank Open Data (CC BY-NC 4.0)
Cefiderocol
Additional database identifiers
ChemSpider
52084902
UniProt Accession
Q51504_PSEAI
GenBank Gene Database
U73780
GenBank Protein Database
1763284
UniProt Accession
PBPA_PSEAE
GenBank Gene Database
AF147449
GenBank Protein Database
4887211
UniProt Accession
Q9X6W0_PSEAI
UniProt Accession
Q9X6V3_PSEAI
GenBank Gene Database
X59460
GenBank Protein Database
41216
UniProt Accession
DACB_ECOLI
HUGO Gene Nomenclature Committee (HGNC)
HGNC:399
GenAtlas
ALB
GeneCards
ALB
GenBank Gene Database
V00494
GenBank Protein Database
28590
UniProt Accession
ALBU_HUMAN
GenBank Gene Database
L11616
GenBank Protein Database
438853
UniProt Accession
MEXA_PSEAE
UniProt Accession
MEXB_PSEAE
UniProt Accession
OPRM_PSEAE
UniProt Accession
FIU_ECOLI
GenBank Gene Database
J04229
GenBank Protein Database
145544
UniProt Accession
CIRA_ECOLI
UniProt Accession
A0A0H2ZGX7_PSEAB
DrugBank citations
If you use DrugBank data in your research, please cite the following publications:
Show earlier publications
Structured knowledge from the free knowledge base
Linked open data from Wikidata (Q27289472), a free and open knowledge base operated by the Wikimedia Foundation. Data is available under the Creative Commons CC0 1.0 Public Domain Dedication.